載入中
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
一般交易時段
US$2.83
+US$0.01 · +0.35%
盤中時間採用ET。市場資料可能有所延遲。
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
日內區間
目前US$2.83
52週區間
目前US$2.83
盤中時間採用ET。市場資料可能有所延遲。
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
日內區間
目前US$2.83
52週區間
目前US$2.83
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 276.32萬 USD | 608.34萬 USD | 385.92萬 USD | 691.08萬 USD | 632.81萬 USD |
| 銷售、一般及管理費用 | 1200.85萬 USD | 931.01萬 USD | 1320.46萬 USD | 1598.14萬 USD | 2337萬 USD |
| 營業費用 | 1530.24萬 USD | 1613.63萬 USD | 2378.95萬 USD | 2742.96萬 USD | 3374.37萬 USD |
| 利息收入 | 23.61萬 USD | 57.29萬 USD | 78.64萬 USD | 36.77萬 USD | 1292 USD |
| 利息支出 | 61.86萬 USD | 4.76萬 USD | 299 USD | 4.88萬 USD | 6.94萬 USD |
| 折舊和攤銷 | 54.58萬 USD | 49.06萬 USD | 250.63萬 USD | 453.46萬 USD | 404.55萬 USD |
| 營業利益 | −1530.24萬 USD | −1613.63萬 USD | −2378.95萬 USD | −2742.96萬 USD | −3374.37萬 USD |
| 淨利 | −2617.53萬 USD | −1420.27萬 USD | −1790.22萬 USD | −2360.68萬 USD | −3528.54萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年8月15日 | 1:65 | — | — |
股票分割 | 2019年10月16日 | 1:201 | — | — |
已生效 2024年8月15日
1:65
已生效 2019年10月16日
1:201
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
